| Literature DB >> 31984145 |
Ruchi Goel1, Akash Raut1, Ayushi Agarwal1, Shweta Raghav1, Sumit Kumar1, Simmy Chaudhary2, Priyanka Golhait1, Sushil Kumar1, Ravindra Saran3.
Abstract
Castleman's disease (CD) is an uncommon group of atypical lymphoproliferative disorders. Extranodal involvement such as the orbit is extremely rare. We aim to report a case of a 62-year-old male who presented with left painless proptosis for the past three years. Examination revealed a firm, lobulated mass in the left superotemporal orbit, displacing the globe inferomedially. A well-defined extraconal orbital lesion encasing the left lateral rectus muscle with intraconal extension was seen on Magnetic Resonance Imaging (MRI) that led to the provisional diagnosis of left solitary encapsulated venous malformation. Excision of the mass via lateral orbitotomy was performed. However, on histopathology, the features were consistent with a mixed-cell variant of Castleman's disease. A detailed systemic workup was unremarkable. Proptosis resolved after surgery and no recurrence was noted in the three-year follow-up. To the best of our knowledge, this is the first case report of a mixed-cell variant of unicentric orbital CD without any systemic features. This case highlights the importance of including CD in the differential diagnosis of well-defined orbital lesions so as to enable its early detection and timely management.Entities:
Year: 2020 PMID: 31984145 PMCID: PMC6964713 DOI: 10.1155/2020/1012759
Source DB: PubMed Journal: Case Rep Ophthalmol Med
Figure 1Clinical photograph showing left superior orbital fullness displacing the eyeball inferomedially.
Figure 2CE-MRI (Contrast-Enhanced Magnetic Resonance Imaging) showing left well-defined orbital lesion in the extraconal compartment abutting the left lateral rectus muscle with intraconal extension.
Figure 3Gross examination showing a 3.5 × 3 × 2 cm well-defined, greyish-red, lobulated, and firm mass.
Figure 4Histopathology suggestive of extranodal CD revealed (a) extranodal tissue showing a dilated blood vessel (black arrow) with multiple sheaths of lymphoid cells with attempted ill-formed follicles (white arrow) (HES2X), (b) mature looking lymphocytes (white arrow) (HES40X), (c) follicular dendritic cells positive for CD23 (black arrow) with garlanding (“onion skinning”) of lymphocytes around it (white arrow), (d) polyclonal expression of kappa and (e) lambda, and (f) CD138-positive for plasma cells (g) CD5-positive T cells and (h) cytotoxic CD8 cells.
Management of CD: an overview.
| Treatment | Prognosis | |
|---|---|---|
| Unicentric (orbital) CD | Surgery (cornerstone)±neoadjuvant chemotherapy alternative: radiotherapy | Surgery: excellent prognosis with 10-year survival rate > 95% |
|
| ||
| Multicentric CD | (i) Cytotoxic chemotherapy (CHOP/etoposide/CVAD/COP) | Multicentric CD has a long-term poor prognosis (worst in idiopathic MCD) |
CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisolone; CVAD: cyclophosphamide, vincristine, doxorubicin, dexamethasone; COP: cyclophosphamide, vincristine, prednisolone.